NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TNXP

Tonix Pharmaceuticals Holding Corp

Jul 11 • 04:00PM ET

40.87

Dollar change -1.49
Percentage change -3.52	%

Healthcare • Biotechnology • USA • NASD

Peers: DMAC KRRO ACIU ELDN INBX INMB VYGR TVGN SOPH BTMD

| Held by: IWM VXF IWN FESM VFMO IWC ITOT RSSL SBIO DFAT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2930.78	Insider Own	0.07%	Shs Outstand	7.36M	Perf Week	15.19%
Market Cap	300.69M	Forward P/E	-	EPS next Y	-6.08	Insider Trans	347.81%	Shs Float	7.35M	Perf Month	8.29%
Enterprise Value	169.53M	PEG	-	EPS next Q	-5.18	Inst Own	6.77%	Short Float	16.45%	Perf Quarter	128.20%
Income	-131.93M	P/S	29.95	EPS this Y	93.08%	Inst Trans	200.30%	Short Ratio	1.36	Perf Half Y	41.86%
Sales	10.04M	P/B	1.56	EPS next Y	50.29%	ROA	-80.39%	Short Interest	1.21M	Perf YTD	23.92%
Book/sh	26.23	P/C	2.28	EPS next 5Y	88.07%	ROE	-91.44%	52W High	130.00 -68.56%	Perf Year	-32.13%
Cash/sh	17.90	P/FCF	-	EPS past 3/5Y	52.42% 73.03%	ROIC	-73.00%	52W Low	6.76 504.59%	Perf 3Y	-99.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	2.98%	Volatility	8.48% 8.67%	Perf 5Y	-99.99%
Dividend TTM	-	EV/Sales	16.89	EPS Y/Y TTM	83.49%	Oper. Margin	-721.51%	ATR (14)	3.16	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	11.64	Sales Y/Y TTM	-2.04%	Profit Margin	-1313.87%	RSI (14)	62.14	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.31	EPS Q/Q	99.52%	SMA20	14.40%	Beta	1.71	Target Price	61.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-2.14%	SMA50	28.82%	Rel Volume	0.69	Prev Close	42.36
Employees	81	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	79.47%	Avg Volume	888.98K	Price	40.87
IPO	Feb 03, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	8.09% -6.58%	Trades		Volume	610,840	Change	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy	$4
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy	$6
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform	$18 → $10
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform	$18
Feb-17-15	Reiterated	ROTH Capital	Buy	$10 → $12
Sep-29-14	Reiterated	ROTH Capital	Buy	$17 → $10

Jul-10-25 07:00AM	Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 (GlobeNewswire) +10.43%
Jul-09-25 04:01PM	Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine (GlobeNewswire) +7.87%
Jul-07-25 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 (GlobeNewswire)
Jul-02-25 07:00AM	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models (GlobeNewswire) -5.71%
Jul-01-25 07:23AM	Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes (TipRanks)
07:00AM	Loading…
Jun-30-25 07:00AM	Tonix Pharmaceuticals Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-16-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 (GlobeNewswire) +15.60%
Jun-13-25 07:00AM	Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors (GlobeNewswire) -7.41%
Jun-10-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention (GlobeNewswire)
Jun-05-25 07:00AM	Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 (GlobeNewswire)
May-22-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase (GlobeNewswire) -6.81%
May-21-25 07:00AM	Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction (GlobeNewswire) -5.25%
May-14-25 07:00AM	Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations (GlobeNewswire) +9.42%
May-12-25 04:30PM	Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire) +5.16%
Apr-29-25 09:05AM	Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire)
07:55AM	Loading…
Apr-24-25 07:55AM	Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 (GlobeNewswire) -6.71%
Apr-10-25 09:24AM	Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? (Insider Monkey)
Apr-09-25 07:00AM	Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies (GlobeNewswire) -9.64%
Apr-07-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting (GlobeNewswire) +13.81%
Apr-02-25 07:00AM	Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference (GlobeNewswire)
Apr-01-25 07:00AM	Tonix Pharmaceuticals Launches TONIX ONE , a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition (GlobeNewswire)
Mar-31-25 07:00AM	Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year (ACCESSWIRE) -11.38%
Mar-27-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting (GlobeNewswire) -7.27%
Mar-26-25 02:30AM	Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years (SeekingAlpha)
Mar-25-25 01:00PM	Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (SeekingAlpha)
09:10AM	Pharma Frenzy: Volatility Ignites Biotech Sector (MarketBeat)
Mar-24-25 08:00AM	Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire) +32.48%
Mar-20-25 07:00AM	As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread (ACCESSWIRE) +10.44%
Mar-18-25 04:30PM	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (GlobeNewswire) +26.11% -19.78%
08:35AM	Loading…
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) +9.97%
Mar-13-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
07:30AM	Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target (ACCESSWIRE)
Mar-11-25 07:00AM	Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th (GlobeNewswire)
Mar-10-25 08:00AM	Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate (GlobeNewswire)
Mar-09-25 06:44PM	Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week (Insider Monkey)
Mar-07-25 01:40PM	Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared on Thursday (Insider Monkey) -11.00%
Mar-06-25 01:34PM	A 41% Surge? This Small-Cap Pharma Stock Just Shook Up the Fibromyalgia Market (GuruFocus.com) +33.49%
01:23PM	Tonix Surges 31% Following Positive Phase 3 Fibromyalgia Drug Trial Results (GuruFocus.com)
Mar-05-25 07:00AM	Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit (GlobeNewswire) +40.51%
Mar-04-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia (GlobeNewswire) +5.69%
Feb-07-25 11:43AM	Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500 (Clinical Trials Arena) +10.23%
08:30AM	Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash (GlobeNewswire)
Feb-06-25 08:00AM	Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases (GlobeNewswire) -24.97%
Feb-05-25 07:00AM	Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference (GlobeNewswire)
Feb-04-25 07:00AM	Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer (GlobeNewswire) -21.96%
Feb-03-25 08:05AM	Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split (GlobeNewswire) -54.47%
Jan-08-25 07:00AM	Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access (GlobeNewswire) -11.14%
Jan-07-25 07:00AM	Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences (GlobeNewswire) -7.81%
Dec-23-24 08:00AM	Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia (GlobeNewswire) -34.09%
Dec-17-24 08:00AM	Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia (GlobeNewswire) -37.00%
Dec-16-24 11:40AM	Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +120.37%
Dec-09-24 07:30AM	Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers (ACCESSWIRE)
Dec-03-24 07:00AM	Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires (GlobeNewswire)
Nov-26-24 07:00AM	Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference (GlobeNewswire)
Nov-18-24 04:05PM	Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual (GlobeNewswire) +22.33%
07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting (GlobeNewswire)
Nov-14-24 07:30AM	Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments (ACCESSWIRE)
Nov-13-24 04:05PM	Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting (GlobeNewswire)
09:05AM	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals (GlobeNewswire)
Nov-12-24 08:00AM	Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Nov-05-24 07:55AM	Tonix Pharma Partners for Vaccine Clinical Trial (TipRanks)
Nov-04-24 07:00AM	Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya (GlobeNewswire)
Nov-01-24 07:00AM	Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Tonix Pharmaceuticals to Present at BIO-Europe 2024 (GlobeNewswire) -6.15%
Oct-25-24 08:00AM	Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference (GlobeNewswire)
Oct-24-24 08:00AM	Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 (GlobeNewswire)
Oct-17-24 08:00AM	Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) (GlobeNewswire) +12.83%
Oct-16-24 01:01PM	Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals (GuruFocus.com) +12.77%
08:00AM	Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) (GlobeNewswire)
Oct-09-24 07:28AM	Tonix Pharma Enhances Drug Development with AI Partnership (TipRanks)
Oct-08-24 08:30AM	Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals (GlobeNewswire)
Oct-01-24 01:31PM	AI Security, "Netflix of China", Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances (News Direct) -8.75%
07:30AM	The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions (ACCESSWIRE)
Sep-30-24 07:00AM	Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID) (GlobeNewswire)
Sep-27-24 07:00AM	Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines (GlobeNewswire) +6.88%
Sep-23-24 07:00AM	Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) (GlobeNewswire) -8.54%
Sep-19-24 07:00AM	Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines (GlobeNewswire)
Sep-18-24 07:30AM	New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution (ACCESSWIRE)
Sep-16-24 07:00AM	Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency (GlobeNewswire) -5.93%
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Sep-10-24 07:00AM	Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations (GlobeNewswire) -6.12%
Sep-09-24 07:00AM	Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Talk at Immunology Symposium at the University of Alberta (GlobeNewswire) +15.86%
Sep-06-24 07:00AM	Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek (GlobeNewswire) -10.26%
Sep-04-24 07:00AM	As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL (ACCESSWIRE)
Aug-29-24 07:00AM	Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) (GlobeNewswire) -14.82%
Aug-28-24 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS) (GlobeNewswire) -17.37%
Aug-26-24 10:41AM	Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine (Benzinga) +10.00%
07:00AM	Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801 (GlobeNewswire)
Aug-23-24 07:45AM	Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency (ACCESSWIRE)
Aug-21-24 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS) (GlobeNewswire) -5.26%
Aug-20-24 12:34PM	Tonix initiates Phase II trial for emergency cocaine intoxication treatment (Clinical Trials Arena) -14.61%
07:00AM	Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication (GlobeNewswire)
Aug-19-24 06:00AM	Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Aug-16-24 10:52PM	TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
01:29PM	Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests (Benzinga)
07:00AM	Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency (GlobeNewswire)
Aug-13-24 08:00AM	Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit (GlobeNewswire)
Aug-12-24 08:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain (GlobeNewswire) +7.00%

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEDERMAN SETH	Chief Executive Officer	May 15 '25	Buy	21.55	4,000	86,200	4,005	May 15 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNXP

Tonix Pharmaceuticals Holding Corp

Upgrade your FINVIZ experience